View More Recent Stories
-
Lantern Pharma (LTRN) Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers
-
Lantern Pharma (LTRN) Achieves Key Milestone Towards Development of Molecular Diagnostic with LP-184
-
Lantern Pharma (LTRN) Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
